Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Idiopathic Pulmonary Arterial Hypertension Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Santa Barbara, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00660179
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
macitentan (ACT-064992), placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension

NCT00384865
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Simvastatin, Aspirin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension

NCT00105209
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Aspirin, clopidogrel
Drug
Lead sponsor
Kawut, Steven, MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Pulmonary Hypertension and Anastrozole Trial

NCT03229499
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anastrozole, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 13, 2026, 6:42 PM EDT
Not listed Phase 1 Interventional

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

NCT04503733
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Q4W GMA301 IV injections (300 mg), Q4W GMA301 IV injections (600 mg), Q4W GMA301 IV injections (1000 mg), Q4W GMA301 IV injections (1800 mg), Q4W placebo IV injections
Drug · Other
Lead sponsor
Gmax Biopharm LLC.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on the Pharmacokinetics of Oral Treprostinil

NCT00963001
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Standardized meals
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 13, 2026, 6:42 PM EDT
Recruiting Phase 3 Interventional

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Seralutinib, Gereic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 6:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

NCT01730092
View directory record Official record
Conditions
Pulmonary Disease, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

NCT03145298
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
Allogeneic Human Cardiosphere-Derived Stem Cells, Placebo
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Phase 3 Interventional Results available

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

NCT00795639
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Sitaxsentan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Fountain Valley, California • Mather, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 13, 2026, 6:42 PM EDT
Not listed No phase listed Observational

Non-invasive Pulmonary Artery Prediction (ADOPTS)

NCT05641675
View directory record Official record
Conditions
Heart Failure, Pulmonary Arterial Hypertension
Interventions
right heart catheterization
Diagnostic Test
Lead sponsor
Silverleaf Medical Sciences INC
Industry
Eligibility
20 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

NCT01153386
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Phase 3 Interventional Results available

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00879229
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Results available

Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension

NCT05439460
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Phenylephrine, Epinephrine, Arginine Vasopressin
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 13, 2026, 6:42 PM EDT
Withdrawn Phase 4 Interventional

Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan

NCT01508780
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT), Boston Scientific Intravascular Ultrasound
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated No phase listed Observational

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

NCT00706082
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 13, 2026, 6:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 13, 2026, 6:42 PM EDT
Withdrawn Not applicable Interventional

Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension

NCT04254289
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Usual Care, Home-based exercise program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

NCT00159874
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 13, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

Insulin Resistance in Pulmonary Arterial Hypertension

NCT00825266
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
bosentan, Pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 13, 2026, 6:42 PM EDT
Completed No phase listed Observational

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

NCT01799473
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
51
States / cities
La Jolla, California • Los Angeles, California • Pasadena, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

NCT02932410
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan, Standard-of-care
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
1 Month to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 13, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT05147805
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 13, 2026, 6:42 PM EDT